Charles Paulding

Title: The Innovations of Charles Paulding

Introduction

Charles Paulding is a notable inventor based in Tarrytown, NY (US). He has made significant contributions to the field of medical science, particularly in the treatment of sepsis and cardiovascular risk. With a total of five patents to his name, Paulding's work has the potential to impact patient care and treatment methodologies.

Latest Patents

One of his latest patents focuses on the treatment of sepsis with PCSK9 and LDLR modulators. This patent provides methods for treating subjects with sepsis, SIRS, septic shock, and/or MODS. It also includes methods for identifying subjects at an increased risk of developing these conditions, as well as methods for detecting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) variant nucleic acid molecules and polypeptides. Another significant patent involves genome-based methods for reducing cardiovascular risk. This patent outlines methods for administering a PCSK9 inhibitor to patients with a genetic profile that responds positively to this therapy.

Career Highlights

Charles Paulding is currently employed at Regeneron Pharmaceuticals, Inc., where he continues to innovate and develop new treatments. His work at Regeneron has positioned him as a key player in the pharmaceutical industry, particularly in the areas of genetics and cardiovascular health.

Collaborations

Paulding collaborates with talented individuals such as Lorah Perlee and Sara Hamon, who contribute to his research and development efforts. Their combined expertise enhances the potential for groundbreaking discoveries in their field.

Conclusion

Charles Paulding's contributions to medical science through his patents and collaborations highlight his commitment to improving patient outcomes. His innovative approaches to treating sepsis and reducing cardiovascular risk demonstrate the importance of research and development in healthcare.